Fundraising Fox
SFA Therapeutics
YC S21Philadelphia, US · Founded 2016 · 4 employees · 14 known investors
Find your way into SFA Therapeutics
Sign up to see every warm intro you have to SFA Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the SFA Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.
Also known as SFA Therapeutics, Inc.
Founders & leadership· Y Combinator alumni (S21)
SFA Therapeutics was founded in 2016 by Ira Spector, Alla Arzumanyan, and Mark Feitelson.
Investors · 14
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us
How we know: Farvatn Venture's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Immeasurable's portfolio page · Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Planet 9 Capital's portfolio page · Not right? Tell us
How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: funding news · Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeed RoundJun 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
The YC application· Summer 2021 batch
What they told YC
- What is your company going to make? Please describe your product and what it does or will do.
- SFA Therapeutics is a biotech company developing small-molecule drugs derived from human GI bacterial metabolites that modulate the immune system by downregulating the NF-kB and Ras pathways involved in inflammation and carcinogenesis. The platform has yielded six drug candidates for immuno-inflammatory diseases and inflammation-driven liver diseases, with lead assets SFA001 (liver disease) and SFA002 (autoimmune disease); SFA002 has an approved IND and is ready for clinical trials. The company plans to develop its drugs through Phase 2 and license Phase 3-ready assets to pharma and biotech partners in exchange for license fees, royalties, and milestone payments.
Alumni Q&A
- What is the core problem you are solving? Why is this a big problem? What made you decide to work on it?
- The founders aim to treat autoimmune disease by addressing the underlying disease rather than suppressing the immune system.
- What is your long-term vision? If you truly succeed, what will be different about the world?
- The company's long-term goal is to achieve functional cures for autoimmune diseases.
Summarized from the founders' answers on their Y Combinator profile.
Related companies · 8
Companies working in the same space as SFA Therapeutics.
Legal entities · 1
corporate structureIn the news
Frequently asked questions
- What does SFA Therapeutics do?
- SFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.
- Who founded SFA Therapeutics?
- SFA Therapeutics was founded by Ira Spector, Alla Arzumanyan, Mark Feitelson in 2016.
- Who are SFA Therapeutics's investors?
- SFA Therapeutics's investors include Acequia Capital (AceCap), Farvatn Venture, Immeasurable, North South Ventures, Planet 9 Capital, Y Combinator, Asymmetry Ventures, Ben Franklin Technology Partners and 6 more.
- Where is SFA Therapeutics headquartered?
- SFA Therapeutics is headquartered in Philadelphia, US.